treated prostate cancer (PCa) patients develop biochemical recurrence (BCR) in 27-53% of cases; the role of MRI in this setting is still controversial. In 2021 a panel of experts proposed a "Prostate Imaging-Recurrence Reporting" (PI-RR) score, aiming to standardize the reporting. The aim of our study is to evaluate the reproducibility of the PI-RR scoring system among readers with different expertise.
in this monocentric, retrospective observational study, the images of patients who underwent MRI with BCR from January 2017 to January 2022 were analyzed by two radiologists and a radiology resident. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were obtained. Interobserver agreement was calculated. The percentage of the PI-RR score of 3 was estimated to find out the proportion of uncertain exams reported among the readers.
a total of seventy-six patients were included in our study: eight previously treated with RT and sixty-eight who underwent surgery. The accuracy range was 75-80%, the sensitivity 68.4-71.1%, the specificity 81.6-89.5%, PPV 78.8-87.1%, and NPV 72.1-75.6%. The inter-reader agreement using a binary evaluation (PI-RR ≥ 3 as positive mpMRI) demonstrated a correlation coefficient (k) of 0.74 (95% CI: 0.62-0.87). The percentage for the PI-RR score of 3 was 6.6% for reader one, 14.5% for reader two, and 2.6% for reader three.
this study confirmed the good accuracy of mpMRI in the detection of local recurrence of PCa and the good reproducibility of PI-RR score among all readers, confirming it to be a promising tool for the standardization of the assessment of patients with BCR.
Diagnostics (Basel, Switzerland). 2023 Jan 20*** epublish ***
Chiara Bergaglio, Veronica Giasotto, Michela Marcenaro, Salvina Barra, Marianna Turazzi, Matteo Bauckneht, Alessandro Casaleggio, Francesca Sciabà, Carlo Terrone, Guglielmo Mantica, Marco Borghesi, Alessio Signori, Bruno Spina, Nataniele Piol, Elisa Zanardi, Giuseppe Fornarini, Jeries Paolo Zawaideh, Uro-Oncology Disease Management Team (DMT) of the IRCCS Ospedale Policlinico San Martino Genoa, Italy
Department of Health Sciences (DISSAL), University of Genova, 16126 Genova, Italy., Department of Radiology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy., Department of Radiation Oncology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy., Department of Urology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy., Pathology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy., Anatomia Patologica Universitaria Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy., Academic Unit of Medical Oncology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy., Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.